WO2000004888A3 - Use of cyclodextrins for the treatment of cerebral ischaemia and central nervous system injury - Google Patents
Use of cyclodextrins for the treatment of cerebral ischaemia and central nervous system injury Download PDFInfo
- Publication number
- WO2000004888A3 WO2000004888A3 PCT/GB1999/002311 GB9902311W WO0004888A3 WO 2000004888 A3 WO2000004888 A3 WO 2000004888A3 GB 9902311 W GB9902311 W GB 9902311W WO 0004888 A3 WO0004888 A3 WO 0004888A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- nervous system
- central nervous
- cyclodextrins
- system injury
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU50508/99A AU5050899A (en) | 1998-07-20 | 1999-07-19 | Chemical compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9815785.2A GB9815785D0 (en) | 1998-07-20 | 1998-07-20 | Chemical compounds |
GB9815785.2 | 1998-07-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000004888A2 WO2000004888A2 (en) | 2000-02-03 |
WO2000004888A3 true WO2000004888A3 (en) | 2000-04-27 |
Family
ID=10835840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1999/002311 WO2000004888A2 (en) | 1998-07-20 | 1999-07-19 | Use of cyclodextrins for the treatment of cerebral ischaemia and central nervous system injury |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU5050899A (en) |
GB (1) | GB9815785D0 (en) |
WO (1) | WO2000004888A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6982256B2 (en) | 2001-09-07 | 2006-01-03 | Boehringer Ingelheim Pharma Kg | Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration |
LU100797B1 (en) * | 2018-05-15 | 2019-11-15 | Univ Luxembourg | 2-hydroxypropyl-beta-cyclodextrin for use in a method of treatment of a parkinsonian condition |
WO2023123468A1 (en) * | 2021-12-31 | 2023-07-06 | 杭州奥默医药股份有限公司 | Cardiovascular and cerebrovascular drug and use thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0169725A2 (en) * | 1984-07-23 | 1986-01-29 | Ono Pharmaceutical Co., Ltd. | Prostaglandin analogues for the treatment of brain cells anoxia |
WO1992002256A1 (en) * | 1990-08-01 | 1992-02-20 | The Regents Of The University Of California | Cyclodextrin complexes for neuraxial administration of drugs |
EP0501552A1 (en) * | 1991-02-25 | 1992-09-02 | Janssen Pharmaceutica N.V. | 4-[(2-Benzothiazolyl)methylamino]-alpha-[(3,4-difluorophenoxy)methyl]-1-piperidineethanol |
US5334382A (en) * | 1993-02-25 | 1994-08-02 | Sterling Winthrop Inc. | Lyophilized polyethylene oxide modified catalase composition, polypeptide complexes with cyclodextrin and treatment of diseases with the catalase compositions |
WO1996012472A1 (en) * | 1994-10-24 | 1996-05-02 | Chinoin Gyógyszer És Vegyészeti Termékek Gyára Rt | Liposome composition containing selegilin |
WO1996031220A1 (en) * | 1995-04-03 | 1996-10-10 | The Trustees Of The University Of Pennsylvania | Cyclodextrin compounds and methods of making and use thereof |
WO1997010828A1 (en) * | 1995-09-19 | 1997-03-27 | Weisz Paul B | Therapy for tissue membrane insufficiency |
WO1997049735A1 (en) * | 1996-06-21 | 1997-12-31 | Queen's University At Kingston | Nerve process growth modulators |
-
1998
- 1998-07-20 GB GBGB9815785.2A patent/GB9815785D0/en not_active Ceased
-
1999
- 1999-07-19 WO PCT/GB1999/002311 patent/WO2000004888A2/en active Application Filing
- 1999-07-19 AU AU50508/99A patent/AU5050899A/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0169725A2 (en) * | 1984-07-23 | 1986-01-29 | Ono Pharmaceutical Co., Ltd. | Prostaglandin analogues for the treatment of brain cells anoxia |
WO1992002256A1 (en) * | 1990-08-01 | 1992-02-20 | The Regents Of The University Of California | Cyclodextrin complexes for neuraxial administration of drugs |
EP0501552A1 (en) * | 1991-02-25 | 1992-09-02 | Janssen Pharmaceutica N.V. | 4-[(2-Benzothiazolyl)methylamino]-alpha-[(3,4-difluorophenoxy)methyl]-1-piperidineethanol |
US5334382A (en) * | 1993-02-25 | 1994-08-02 | Sterling Winthrop Inc. | Lyophilized polyethylene oxide modified catalase composition, polypeptide complexes with cyclodextrin and treatment of diseases with the catalase compositions |
WO1996012472A1 (en) * | 1994-10-24 | 1996-05-02 | Chinoin Gyógyszer És Vegyészeti Termékek Gyára Rt | Liposome composition containing selegilin |
WO1996031220A1 (en) * | 1995-04-03 | 1996-10-10 | The Trustees Of The University Of Pennsylvania | Cyclodextrin compounds and methods of making and use thereof |
WO1997010828A1 (en) * | 1995-09-19 | 1997-03-27 | Weisz Paul B | Therapy for tissue membrane insufficiency |
WO1997049735A1 (en) * | 1996-06-21 | 1997-12-31 | Queen's University At Kingston | Nerve process growth modulators |
Non-Patent Citations (7)
Also Published As
Publication number | Publication date |
---|---|
WO2000004888A2 (en) | 2000-02-03 |
AU5050899A (en) | 2000-02-14 |
GB9815785D0 (en) | 1998-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1600168A3 (en) | A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorder | |
AU2002243370A1 (en) | Body supported activity and condition monitor | |
AUPQ514600A0 (en) | Brain injury treatment | |
AU2001279707A1 (en) | Diagnosis of behavioural disorders, neurological disorders and cancer | |
ZA200300712B (en) | Pharmaceutical compositions for the treatment of mucositis, stomatitis and Behcet's syndrome. | |
PL346904A1 (en) | Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas | |
AU6910600A (en) | Methods for the treatment of mental disorders | |
ZA200203156B (en) | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrindependent microcirculation disorders. | |
AU7961200A (en) | Urea derivative, process for producing the same, and medicine containing the urea derivative | |
AUPQ879500A0 (en) | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease | |
AU4373499A (en) | Use of drug-loaded nanoparticles for the treatment of cancers | |
GB2367010B (en) | Body treatment product | |
AU1546101A (en) | Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders | |
WO2000004888A3 (en) | Use of cyclodextrins for the treatment of cerebral ischaemia and central nervous system injury | |
AU3593599A (en) | Drugs for reducing vaginal acidity and treatment of vaginitis, and the use thereof | |
AU778462C (en) | Blood carbonyl compound-trapping agent | |
AU2002215187A1 (en) | S-adenosylmethionine and derivatives thereof for the treatment and prevention ofalzheimer's disease | |
AU2092300A (en) | Use of estrogens and delta-gonadien-21-ol-3,20-diones in the treatment or prophylaxis of cerebral degenerative disorders | |
PL347976A1 (en) | Isonipecotamides for the treatment of integrin−mediated disorders | |
AU3768800A (en) | Treatment of brain changes with myelin protective agents | |
WO2001037832A3 (en) | Combination of riluzole and gabapentin and use thereof as medicine | |
MXPA02006448A (en) | Remedies for external use for allergic skin diseases. | |
AU6107999A (en) | 1,3-benzodiazepines with integrin inhibitory activity for use in the treatment of inflammatory disorders | |
AU4393800A (en) | Security cage for use especially in the inflation of large wheels | |
AU6676100A (en) | Improved treatment for acute physical insult to the central nervous system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |